Literature DB >> 211316

Abnormal low density lipoproteins in children with familial hypercholesterolemia--effect of polyanion exchange resins.

R Mordasini, F Twelsiek, P Oster, B Schellenberg, H Raetzer, C C Heuck, G Schlierf.   

Abstract

In 20 children and adolescents with familial Type II a hyperlipoproteinemia, serum lipids and lipoproteins were examined before and during treatment with polyanion exchange resins. The composition of LDL was compared to that of helthy siblings. The patients were given Colestyramine (0.6 g/kg body weight) and Colestipol (0.5 g/kg body weight) in a cross-over study for 8 weeks each, after they had been under dietary treatment for at least 12 months. In 6 children, drug treatment had to be stopped due to side-effects. The most common complaints were gastrointestinal discomfort and constipation. Cholesterol, triglycerides and phopholipids were measured in whole serum and cholesterol, triglycerides and Apolipoprotein-B in isolated lipoprotein fractions after ultracentrifugation. Apo-B was determined by radial immunodiffusion. The Apo-B: cholesterol ratio in whole serum and in the LDL fraction was identical in the patients and in the controls. The LDL triglyceride: Apo-B ratio, however, was about 50% lower in the patients. This abnormal LDL composition was not altered by therapy with polyanion exchange resins. HDL cholesterol levels were significantly lower in the patients than in healthy children, and remained low during therapy. The decrease of total and LDL cholesterol (25%) and Apo-B (20%) was similar under both Colestipol and Colestyramine. Triglycerides and phospholipids showed no significant changes in therapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 211316     DOI: 10.1007/bf01489714

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  24 in total

1.  Composition of low-density lipoprotein in children with hyperlipoproteinaemia.

Authors:  T F Bagnall; J K Lloyrd
Journal:  Clin Chim Acta       Date:  1975-03-24       Impact factor: 3.786

2.  Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.

Authors:  E A Stein; K W Heimann
Journal:  S Afr Med J       Date:  1975-07-19

3.  [Dietary management of familial Hypercholesterolemia in Children and adolescents -- a feasibility study (author's transl)].

Authors:  G Schlierf; G Vogel; C C Heuck; P Oster; H Raetzer; B Schellenberg
Journal:  Monatsschr Kinderheilkd       Date:  1977-08

4.  Drug therapy of hyperlipoproteinemia.

Authors:  R I Levy
Journal:  JAMA       Date:  1976-05-24       Impact factor: 56.272

5.  Composition of low density lipoprotein in children with familial hyperbetalipoproteinaemia and the effect of treatment.

Authors:  T F Bagnall
Journal:  Clin Chim Acta       Date:  1972-11       Impact factor: 3.786

6.  Diet in children heterozygous for familial hypercholesterolemia.

Authors:  C J Glueck; R C Tsang; R W Fallat; M J Mellies
Journal:  Am J Dis Child       Date:  1977-02

7.  Long-term effects of colestipol (U-26,597 A) on plasma lipids in familial type II hyperbetalipoproteinaemia.

Authors:  R Fellin; G Briani; P Balestrieri; G Baggio; M R Baiocchi; G Crepaldi
Journal:  Atherosclerosis       Date:  1975 Nov-Dec       Impact factor: 5.162

8.  Cholesterol-lowering effect of colestipol hydrochloride given twice daily in hypercholesterolemic patients.

Authors:  K Gundersen; E E Cooper; G Ruoff; T Nikolai; J R Assenzo
Journal:  Atherosclerosis       Date:  1976 Nov-Dec       Impact factor: 5.162

9.  [A comparative study of colestipol and colestyramine in children and adolescents with familial hypercholesterolaemia (author's transl)].

Authors:  R Mordasini; F Twelsick; P Oster; B Schellenberg; H Raetzer; C C Heuck; G Schlierf
Journal:  Monatsschr Kinderheilkd       Date:  1978-07

10.  Cholestyramine: an effective, twice-daily dosage regimen.

Authors:  C B Blum; R J Havlik; J Morganroth
Journal:  Ann Intern Med       Date:  1976-09       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.